Lakefront Biotherapeutics NV current report, Q3 FY2021

Business Context and Reporting Period

This Form 6-K filing is submitted by Galapagos NV, a foreign private issuer, for the month of September 2021. The filing, dated September 20, 2021, serves to incorporate by reference a press release (Exhibit 99.1) issued on the same date. The registrant files annual reports under Form 20-F. Note: The request metadata references "Lakefront Biotherapeutics NV," but the filing text explicitly identifies the registrant as Galapagos NV.

Key Financial Metrics

The filing text does not provide specific financial data. This document is a procedural filing to distribute a press release and does not contain revenue, profit, cash flow, margins, debt, or liquidity figures.

Material Changes

The filing does not detail material changes in financial position or operations. It solely references the issuance of a press release on September 20, 2021, the content of which is not included in the provided text.

Guidance, Outlook, and Risks

The filing text does not contain management commentary, guidance, outlook, risk factors, or details on contingencies and unusual items. These details would be contained within the attached Exhibit 99.1 press release, which is not part of the input text.

Investor Verification Checklist

  • Verify the content of the press release dated September 20, 2021 (Exhibit 99.1), as the filing itself contains no substantive operational or financial data.
  • Confirm the registrant identity is Galapagos NV, not Lakefront Biotherapeutics NV as suggested in the request metadata.
  • Review the incorporated Registration Statements (Forms F-3 and S-8) for broader context on the company's capital structure.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.